What Talis Biomedical Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% owner | Sep 06 | Open-market buy · P | +25,000 | $1.48 | +$37.1K | 248,702 |
| Leonard Braden Michael | 10% owner | Sep 05 | Open-market buy · P | +5,100 | $1.40 | +$7.14K | 223,702 |
| Leonard Braden Michael | 10% owner | Sep 03 | Open-market buy · P | +500 | $4.00 | +$2K | 218,602 |
| Leonard Braden Michael | 10% owner | Aug 30 | Open-market buy · P | +151 | $4.25 | +$642 | 218,602 |
| Leonard Braden Michael | 10% owner | Aug 28 | Open-market buy · P | +1,215 | $3.96 | +$4.81K | 217,951 |
| Leonard Braden Michael | 10% owner | Aug 26 | Open-market buy · P | +13,167 | $3.90 | +$51.3K | 216,736 |
| Baker Bros. Advisors Lp | Director | Nov 18 | Open-market buy · P | +50,000 | $4.37 | +$218K | 7,053,176 |
| Ramakrishnan Ramesh | Insider | Aug 13 | Open-market sale · S | −27,502 | $7.66 | −$211K | 38,619 |
| Ramakrishnan Ramesh | Insider | Aug 13 | Exercise / conversion · M | +8,741 | $1.50 | +$13.1K | 66,121 |
| Ramakrishnan Ramesh | Insider | Aug 13 | Exercise / conversion · M | +43,614 | $1.50 | +$65.4K | 57,380 |
| Scott Randal W | Director | May 17 | Open-market buy · P | +11,000 | $10.11 | +$111K | 20,000 |
| Scott Randal W | Director | May 14 | Open-market buy · P | +9,000 | $10.16 | +$91.4K | 9,000 |
| Posard Matthew L. | Director | Feb 17 | Open-market buy · P | +62,500 | $16.00 | +$1M | 62,500 |
| Scott Randal W | Director | Feb 17 | Open-market buy · P | +312,500 | $16.00 | +$5M | 312,500 |
| Scott Randal W | Director | Feb 17 | Derivative Conversion · C | +302,621 | — | — | 1,390,064 |
| Scott Randal W | Director | Feb 17 | Derivative Conversion · C | +334,546 | — | — | 1,087,443 |
| Scott Randal W | Director | Feb 17 | Derivative Conversion · C | +752,897 | — | — | 752,897 |
| Popovits Kimberly J | Director | Feb 17 | Derivative Conversion · C | +89,968 | — | — | 182,025 |
| Popovits Kimberly J | Director | Feb 17 | Derivative Conversion · C | +92,057 | — | — | 92,057 |
| Popovits Kimberly J | Director | Feb 17 | Open-market buy · P | +5,300 | $16.00 | +$84.8K | 215,090 |
Loading...
